Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.63 |
| ▸ | CKS1B | P61024 | 1/20 | 0.58 |
| ▸ | SKP1 | P63208 | 1/20 | 0.58 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649039 | 0.93 | CKS1B (0.65) | GPR119CKS1BSKP1SKP2NAMPT | |
| SCHEMBL1401967 | 0.87 | GPR119 (0.58) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL1401964 | 0.87 | GPR119 (0.58) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL3884233 | 0.83 | DRD2 (0.55) | GPR119CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL30599874 | 0.82 | PDE10A (0.57) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL21227871 | 0.82 | PDE10A (0.57) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL4377986 | 0.81 | GPR119 (0.55) | GPR119CKS1BSKP1SKP2LMNA | |
| Hydrochloric Acid SCHEMBL240066 | 0.81 | KDM4E (0.51) | GPR119LMNAALDH1A1KDM4EUSP2 | |
| SCHEMBL18901560 | 0.81 | GPR119 (0.54) | GPR119CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL13633563 | 0.80 | LMNA (0.52) | GPR119LMNAALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| EP-2013211-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | GPR119 1142/4885CKS1B 2652/4885SKP1 2054/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | GPR119 1142/4885CKS1B 2652/4885SKP1 2054/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | GPR119 1142/4885CKS1B 2652/4885SKP1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.